Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yoko Korenaga Fukuda"'
Autor:
Yoko Korenaga Fukuda, Jeffrey W. Clark, Shirish M. Gadgeel, Pasi A. Jänne, Patrick M. Forde, Giulia Costanza Leonardi, Sasha Kravets, Viola W. Zhu, Daniel B. Costa, Lynette M. Sholl, Sai-Hong Ignatius Ou, D. Ross Camidge, Rebecca S. Heist, Suzanne E. Dahlberg, Tony Mok, Alexander Drilon, Mark M. Awad, Sinead A. Noonan, Conor E. Steuer
Publikováno v:
Lung Cancer
Objectives Although dramatic responses to MET inhibitors have been reported in patients with MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC), the impact of these treatments on overall survival in this population is unknown. Methods We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3357303dbbdb142ce4f034ce38f5ec63
https://pubmed.ncbi.nlm.nih.gov/31200835
https://pubmed.ncbi.nlm.nih.gov/31200835
Autor:
Larry Rubinstein, Erich P. Huang, Naoko Takebe, Shanda Finnigan, Yoko Korenaga Fukuda, Dai Chihara, Lisa M. Cordes, Nebojsa Skorupan
Publikováno v:
Blood. 136:18-18
Background Phase I study is an essential step of drug development to assess safety, but more recently also to investigate initial insights into potential patient therapeutic response. In the last two decades, treatment of hematologic malignancy has c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9899935ed8051885b1303bb18cf884e4
https://doi.org/10.1182/blood-2020-140159
https://doi.org/10.1182/blood-2020-140159
Autor:
Sinead A. Noonan, Jeffrey W. Clark, Conor E. Steuer, Lynette M. Sholl, Sai-Hong Ignatius Ou, Daniel B. Costa, Viola W. Zhu, Alexander Drilon, Suzanne E. Dahlberg, Tony Mok, Sasha Kravets, D. Ross Camidge, Yoko Korenaga Fukuda, Shirish M. Gadgeel, Patrick M. Forde, Giulia Costanza Leonardi, Mark M. Awad, Pasi A. Jänne, Rebecca S. Heist
Publikováno v:
Journal of Clinical Oncology. 35:8511-8511
8511 Background: Dramatic responses to MET inhibitors have been reported in patients with NSCLC harboring activating mutations that cause MET exon 14 ( METdel14) skipping. We conducted a multicenter retrospective analysis of pts with METdel14 NSCLC t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c84fec86621a2fa081a77efc364d3373
https://doi.org/10.1200/jco.2017.35.15_suppl.8511
https://doi.org/10.1200/jco.2017.35.15_suppl.8511
Autor:
Erich Huang, Yoko Korenaga Fukuda, Naoko Takebe, Larry Rubinstein, S. Percy Ivy, Shanda Finnigan
Publikováno v:
Journal of Clinical Oncology. 32:2552-2552
2552 Background: The primary objective of phase I clinical trials is to evaluate the tolerability and pharmacokinetics of a new agent. Phase I trials in oncology remain ethically controversial. Our previous analysis from year 1991 through 2002 report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf71a3f02e07b3926070a84b5e05c1e5
https://doi.org/10.1200/jco.2014.32.15_suppl.2552
https://doi.org/10.1200/jco.2014.32.15_suppl.2552